ArticleFrontiers in epidemiology2025
Prevalence and associated factors of recent HIV-1 infection among newly identified HIV-positive individuals tested with the Asante Rapid Recency assay in Harari region, Eastern Ethiopia.
Article in Frontiers in epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HIV-1 infection recency among individuals newly diagnosed with HIV in Greater Gaborone, Botswana.AIDS (London, England) · 2025Article
- HIV-1 prevalence, drug resistance, and associated factors in the urban Ethiopian population.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human immunodeficiency virus (HIV) is a virus that attacks the immune system. Globally, more than 79.3 million people have been infected with it, and about 36.3 million people have died since the beginning of the epidemic. Ethiopia is one of the major affected countries in sub-Saharan Africa, with a huge number of people living with HIV. The identification of recent HIV-1 infections plays a crucial role in guiding prevention and control interventions. Moreover, data on the prevalence and factors associated with recent HIV-1 infection among cases tested by the Asante Rapid Recency Assay at health facilities in the Harari region has been inadequate. This study aimed to assess the prevalence and associated factors of recent HIV-1 infection among newly identified HIV-positive individuals tested with the Asante Rapid Recency Assay in Health Facilities of Harari Region, Eastern Ethiopia. Methods: Retrospective cross-sectional study was employed using HIV-1 diagnoses data from April 15-20, 2024 with 580 study participants. The data were extracted based on the standardized HIV Case-Based Surveillance report form, as outlined by the Ethiopian Public Health Institute. Data extracted from Redcap were checked and cleared for completeness then entered and analysed using the Statistical Package for Social Science software version 27. Bivariate and multivariable regression analyses were carried out to examine the associations between dependent and independent variables. A Results: The overall prevalence of recent HIV infection was 9.1% (95% CI: 7.0%, 11.8%). The highest proportion of recent HIV infections was in the year 2019 [9(22.5%)]. The study also found that no formal education (AOR = 18.424, 95% CI = 1.468-231.2), primary educational level (AOR = 22.1, 95% CI = 1.91-256.1, Conclusion: This study found a 9.1% proportion of recent HIV infections, indicating significant ongoing HIV transmission within the community. The study also revealed multiple risk factors for recent HIV infection, including lower educational levels, recent sexual activity, sex with high-risk partners, and drug use. This study emphasizes the significance of improving targeted HIV preventive programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.